Some important questions the story didn’t address: how did researchers measure development/intelligence at 18 months? What effect size were they hoping for?
In a few small but significant ways, this story used language that explained the findings more clearly than the competing New York Times story. But both stories whiffed on some important questions. Read both full reviews to learn more.
There was no discussion of costs and we always think there should be – even if inconsequential.
Overall, we would have wished for more specificity on the data that was reported. There were glimpses of specifity, as when the story reported: "The latest study does suggest that some subgroups of women might benefit from fish-oil supplements. For instance, those with a history of clinical depression—and thus are at higher risk of post-partum depression—who took 800 milligrams of fish oil daily lowered their risk of getting depressed after the birth by about 4% compared with those who didn’t take fish oil. However, the difference wasn’t statistically significant because of the small number of women in the study who had been previously depressed, said Dr. Makrides, who is also a professor of human nutrition at the University of Adelaide."
But we were disappointed that the story didn’t disclose how much preterm birth risk was reduced – an issue of vital concern to many readers. A preemie and an induction (covered as a harm but also without any numbers provided) aren’t necessarily equal.
On balance, we just didn’t get enough data on benefits.
There was no broad discussion of safety or side effects. But one issue was raised that was not in the NYT story:
"Women in the fish-oil group had lower rates of pre-term births, particularly births earlier than 34 weeks of gestation. But, there was a trade-off: More women who took the supplement needed their labor to be induced or had caesarean sections because the babies stayed in the womb longer, said Dr. Makrides."
Because it at least nodded in the direction of a specific potential harm issue, this story gets a satisfactory score on this criterion.
Satisfactory job and in little ways superior to the NYT story we reviewed on the same study. For example, the language in this story was much more clear and helpful:
"Several previous studies have shown that eating fish during pregnancy helped in the baby’s brain development and in reducing the risk of post-partum depression. That research, however, typically didn’t involve randomized, controlled studies. Instead, women were asked whether or not they chose to eat fish during pregnancy. It could be the case that eating fish is better than taking fish-oil supplements or that women who opt to eat fish are generally healthier and engage in other health-promoting behaviors, Dr. Oken said. The few trials conducted that separated participants, into a group taking fish-oil supplements and another that didn’t, weren’t well done, because the women often knew if they were getting the supplement, and in some cases there wasn’t a comparison group at all, she said."
Barely adequate – in that the story at least cited the views of an editorial writer in addition to those of one of the study authors.
Again, barely adequate in that the story at least discussed a bit about both DHA supplements and fish consumption – but wrapped this into broader healthy alternatives such as "all pregnant women should strive for balance and eat a variety of foods, including fish."
The story makes it clear that fish oil is widely available and has been widely used for the described uses. However, it would have been helpful for readers/consumers if the story had discussed the challenge of assessing product purity, quality control, etc. – that it’s not just a simple matter of "just take fish oil."
Past research on this topic is covered quite clearly.
It’s clear that the story did not rely on a news release.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like